iBio
IBIO
29 hedge funds and large institutions have $3.45M invested in iBio in 2023 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 7 reducing their positions, and 13 closing their positions.
248% more capital invested
Capital invested by funds: $990K → $3.45M (+$2.46M)
71% more call options, than puts
Call options by funds: $1.32M | Put options by funds: $773K
0.42% less ownership
Funds ownership: 1.09% → 0.67% (-0.42%)
14% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 7
22% less funds holding
Funds holding: 37 → 29 (-8)
62% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$676K |
| 2 |
Bank of New York Mellon
New York
|
+$113K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$56.2K |
| 4 |
State Street
Boston,
Massachusetts
|
+$22.1K |
| 5 |
HighTower Advisors
Chicago,
Illinois
|
+$15.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$631K |
| 2 |
Renaissance Technologies
New York
|
-$404K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$173K |
| 4 |
BlackRock
New York
|
-$169K |
| 5 |
Millennium Management
New York
|
-$31K |
IBIO Hedge Fund Activity: Q1 2023 in Review
29 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in iBio (IBIO) for Q1 2023, worth a combined $3.45M — up 248% from $990K a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of IBIO and 5 opened new positions — a net loss of 8 holders — while 7 trimmed existing stakes and 6 added.
The largest buyer was Armistice Capital, opening a new position worth an estimated $676K. The largest seller was Sabby Management, exiting entirely with an estimated $631K sold.
- 29 institutional investors held iBio (IBIO) as of Q1 2023, down from 37 in Q4 2022.
- Funds reported $3.45M of iBio stock for Q1 2023, up 248% quarter-over-quarter.
- 5 funds opened new iBio positions in Q1 2023 and 13 closed out, a net change of -8 holders.
- The largest iBio buyer in Q1 2023 was Armistice Capital, an estimated $676K added.
- The largest iBio seller in Q1 2023 was Sabby Management, an estimated $631K sold.
Based on aggregated 13F filings for Q1 2023.